Phaseline

Companies › Nanjing Chia-tai Tianqing Pharmaceutical

Nanjing Chia-tai Tianqing Pharmaceutical: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 1 Phase 1, 1 Phase 2; Metabolic and endocrine, Hematology; next expected readout Apr 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
NTQ5082
Factor B (CFB) inhibitor
CFBPhase 2Paroxysmal Nocturnal HemoglobinuriaJul 2027
NTQ6179
somatostatin receptor subtype 2 (SSTR2) agonist
SSTR2Phase 1AcromegalyApr 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07909837NTQ6179Phase 1AcromegalyMetabolic and endocrineApr 2027
NCT06764303NTQ5082Phase 2Paroxysmal Nocturnal HemoglobinuriaHematologyJul 2027

Targets

SSTR2 (1) CFB (1)

Companies with the same targets

Novartis Sinotau Pharmaceutical Group HTA RayzeBio ITM Solucin Orano Med Camurus Jiangsu HengRui Medicine Advanced Accelerator Applications CSPC ZhongQi Pharmaceutical Technology

Companies built like this

Agios Pharmaceuticals Marea Therapeutics Biomea Fusion Jiangsu BioJeTay Biotechnology JCR Pharmaceuticals

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.